ArticleCureus2025
Multifocal Inflammatory Myofibroblastic Tumor Presenting With Hemorrhagic Shock Due to Duodenal Invasion by a Pancreatic Head Mass: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm of intermediate malignant potential. Although typically indolent, IMT can occasionally exhibit aggressive behavior, including distant metastasis or multifocal involvement. Clinical manifestations vary widely according to anatomic location. Gastrointestinal tract involvement has been reported; however, massive gastrointestinal bleeding leading to hemorrhagic shock is exceedingly rare. We present a 56-year-old man who presented with melena and hemorrhagic shock. Imaging demonstrated a pancreatic head mass with duodenal ulceration, along with a pulmonary nodule and multiple renal lesions. Endoscopic hemostasis was unsuccessful, and transcatheter arterial embolization (TAE) achieved temporary bleeding control. The patient subsequently underwent pancreaticoduodenectomy for definitive hemostasis and local disease management. Histopathologic examination of the pancreatic mass demonstrated spindle cell proliferation consistent with IMT and negative immunoreactivity for anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and other relevant markers. Systemic evaluation revealed multifocal disease involving the brain, parotid gland, lungs, heart, liver, pancreatic tail, kidneys, adrenal gland, lymph nodes, and bones. Dynamic contrast-enhanced magnetic resonance imaging (MRI) of the parotid lesion showed gradual, continuous enhancement, consistent with a fibrous-rich lesion. Based on biopsies from multiple sites and the overall clinical course, a diagnosis of multifocal IMT was established. Initial systemic therapy with doxorubicin achieved stable disease at three months. Based on the genomic findings identified following comprehensive genomic profiling, the patient was subsequently enrolled in the DESTINY-PanTumor02 clinical trial and transitioned to treatment with trastuzumab deruxtecan targeting the human epidermal growth factor receptor 2 (HER2) alteration. Our case represents an exceptionally rare presentation of IMT, characterized by life-threatening gastrointestinal bleeding and extensive multifocal dissemination. It illustrates the marked radiologic and clinicopathologic heterogeneity of IMT and emphasizes the importance of comprehensive histopathologic and molecular evaluation to guide management in aggressive disease variants. Close collaboration across cross-disciplinary diagnostic specialties is essential for the assessment and treatment of rare, multi-organ conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.